Harmony Biosciences Holdings (HRMY) Cash & Current Investments (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Cash & Current Investments data on file, last reported at $523.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 3.34% year-over-year to $523.9 million; the trailing twelve-month figure through Mar 2026 stood at $523.9 million (up 3.34% YoY), and the FY2025 full-year result was $378.4 million, down 14.15% from the prior year.
• Cash & Current Investments grew to $523.9 million in Q1 2026, from $378.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $672.6 million in Q3 2025 to a low of $212.2 million in Q2 2022.
• A 5-year average of $405.3 million and a median of $378.4 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 74.82% in 2023 and retreated 14.15% in 2025, its largest moves.
• Tracing HRMY's Cash & Current Investments over 5 years: stood at $366.2 million in 2022, then slipped by 3.48% to $353.5 million in 2023, then rose by 24.71% to $440.8 million in 2024, then dropped by 14.15% to $378.4 million in 2025, then jumped by 38.44% to $523.9 million in 2026.
• Business Quant data shows HRMY's Cash & Current Investments at $523.9 million in Q1 2026, $378.4 million in Q4 2025, and $672.6 million in Q3 2025.